regulator of G protein signaling 13Genealiases: []
Q-omics provides the consensus-scored RGS13 profile across patient tissues and cancer cell-line models. RGS13 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RGS13 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RGS13 RNA expression shows 13,205 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, COAD, and KIRP as cancer lineages where RGS13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS13 survival associations across molecular data types. RGS13 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS13 RNA expression–survival associations across cancer types. High RGS13 expression shows unfavorable associations in LGG, but favorable associations in HNSC, COAD, LUAD, SKCM and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RGS13 RNA expression.
This table summarizes RGS13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RGS13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS13 shows lower tumor expression in COAD, BLCA, LUAD, LUSC and UCEC and higher tumor expression in KIRC. The COAD box plot shows higher RGS13 RNA expression in normal versus tumor tissue (log2 FC = −1.150, t-test p < 0.001).
This table shows molecular features associated with RGS13 in patient tissues and cancer cell lines. In patient samples, RGS13 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
